Alf Lindberg

Title: The Innovative Contributions of Alf Lindberg

Introduction

Alf Lindberg is a notable inventor based in Lyons, France. He has made significant contributions to the field of immunology, particularly in the development of vaccines. With a total of 2 patents, his work focuses on enhancing the immunogenicity of bacterial meningitis vaccines.

Latest Patents

Lindberg's latest patents include the development of multi-oligosaccharide glycoconjugate bacterial meningitis vaccines. These multivalent immunogenic molecules consist of a carrier molecule that contains at least one functional T-cell epitope and multiple different carbohydrate fragments. Each fragment is linked to the carrier molecule and contains at least one functional B-cell epitope. The carrier molecule enhances the immunogenicity of the carbohydrate fragments, which may include capsular oligosaccharide fragments from various serotypes. The fragments can range in size from 2 to 5 kDa and may also include carbohydrate-based tumor antigens. These multivalent molecules can be produced through random or site-directed conjugation and are intended for use in vaccines or antibody generation for diagnostic applications.

Career Highlights

Alf Lindberg is currently associated with Aventis Pasteur Limited, a leading company in vaccine development. His work has been instrumental in advancing the field of immunology and vaccine research.

Collaborations

Lindberg has collaborated with notable coworkers such as Pele Chong and Michel Henri Klein. Their combined expertise has contributed to the success of various projects in the field of vaccine development.

Conclusion

Alf Lindberg's innovative work in the development of bacterial meningitis vaccines showcases his dedication to improving public health through scientific research. His contributions continue to influence the field of immunology and vaccine technology.